Immunothrombotic dysregulation in chagas disease and COVID-19: a comparative study of anticoagulation

Mol Cell Biochem. 2021 Oct;476(10):3815-3825. doi: 10.1007/s11010-021-04204-3. Epub 2021 Jun 10.


Chagas and COVID-19 are diseases caused by Trypanosoma cruzi and SARS-CoV-2, respectively. These diseases present very different etiological agents despite showing similarities such as susceptibility/risk factors, pathogen-associated molecular patterns (PAMPs), recognition of glycosaminoglycans, inflammation, vascular leakage hypercoagulability, microthrombosis, and endotheliopathy; all of which suggest, in part, treatments with similar principles. Here, both diseases are compared, focusing mainly on the characteristics related to dysregulated immunothrombosis. Given the in-depth investigation of molecules and mechanisms related to microthrombosis in COVID-19, it is necessary to reconsider a prompt treatment of Chagas disease with oral anticoagulants.

Keywords: COVID-19; Hyperaggregability; Hypercoagulability; Immunothrombosis; Platelet; SARS-CoV-2.

Publication types

  • Comparative Study

MeSH terms

  • Anticoagulants / therapeutic use*
  • Blood Platelets / immunology
  • COVID-19 / immunology
  • COVID-19 / pathology*
  • Chagas Disease / immunology
  • Chagas Disease / pathology*
  • Complement Activation / immunology
  • Endothelium / pathology
  • Heparitin Sulfate / therapeutic use*
  • Humans
  • Pathogen-Associated Molecular Pattern Molecules / immunology
  • Platelet Activation / immunology
  • SARS-CoV-2 / immunology
  • Thrombosis / drug therapy*
  • Thrombosis / pathology*
  • Trypanosoma cruzi / immunology


  • Anticoagulants
  • Pathogen-Associated Molecular Pattern Molecules
  • Heparitin Sulfate